Fluorescent humanized anti-CEA antibody specifically labels metastatic pancreatic cancer in a patient-derived orthotopic xenograft (PDOX) mouse model.
Fluorescent humanized anti-CEA antibody specifically labels metastatic pancreatic cancer in a patient-derived orthotopic xenograft (PDOX) mouse model.
复制标题
DOI：
10.18632/oncotarget.26484
复制
发表时间：
2018-12-18
期刊：
影响因子：
--
通讯作者：
Bouvet, Michael
中科院分区：
文献类型：
--
作者：
Lwin, Thinzar M;Miyake, Kentaro;Bouvet, Michael
胰腺癌是一种高度致命的疾病，部分原因是肿瘤切除不完全。通过与荧光标记缀合的肿瘤特异性抗体的靶向可以导致在体内选择性标记癌症以用于手术导航。在本研究中，我们描述了一种源自患者的胰腺癌原位异种移植模型，该模型在大体和显微镜水平上概括了该疾病，沿着有生理临床表现。我们还表明，使用与近红外（NIR）荧光染料IRDye800CW偶联的抗CEA抗体，可以选择性地突出显示胰腺癌及其在该模型中的转移，肿瘤与背景比为3.5（SEM 0.9）。目前的结果表明，这种标记技术的荧光引导手术的胰腺癌的临床潜力。
Pancreatic cancer is a highly lethal disease in part due to incomplete tumor resection. Targeting by tumor-specific antibodies conjugated with a fluorescent label can result in selective labeling of cancer in vivo for surgical navigation. In the present study, we describe a patient-derived orthotopic xenograft model of pancreatic cancer that recapitulated the disease on a gross and microscopic level, along with physiologic clinical manifestations. We additionally show that the use of an anti-CEA antibody conjugated to the near-infrared (NIR) fluorescent dye, IRDye800CW, can selectively highlight the pancreatic cancer and its metastases in this model with a tumor-to-background ratio of 3.5 (SEM 0.9). The present results demonstrate the clinical potential of this labeling technique for fluorescence-guided surgery of pancreatic cancer.